Faisal Farrash

Dr. Faisal Farrash

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Cureus
Verified
Journal Article
Open access
PDF file
HAHammam Alotaibi
Hammam Alotaibi
Stefano Maria PriolaStefano Maria Priola
Stefano Maria Priola
ABAnne-Laure Bernat
Anne-Laure Bernat
Faisal FarrashFaisal Farrash
Faisal Farrash
Esthesioneuroblastoma (ENB) is a rare malignant tumor of the nasal cavity. The genetic basis of its development is still under study and has not been fully delineated. It has varying symptoms depending on the lesion’s location within the nasal cavity. The most commonly used systems for such lesions are the Kadish staging and Haymes grading systems. The objectives are to review the most recent published literature evaluating the different treatments/ combination of treatment and assess the most appropriate treatment modality that can provide the longest progression-free survival and overall survival for ENB patients. Moreover, a look at what the latest literature suggests when it comes to adjuvant treatments and their effect on survival is also key to further the body of knowledge for neurosurgeons, Ears, Nose, and Throat (ENT) physicians and all the different subspecialties that deal and serve these population of patients. The published literature was reviewed starting from 1990. The focus was made on single-center experiences given their availability and easy access. The most recently published systematic review was used as the benchmark; research published after that was included in this study. The database search in OVID was conducted using the following keywords: “Esthesioneuroblastoma”, “ENB”, “Olfactory Neuroblastoma”, Nose neoplasm”, skull base neoplasm”, “radiation”, and “resection”. The database search found 17 papers which included 14 single-center reports, one systematic review, and two nationwide multi-center reviews. Surgery plus adjuvant radiation therapy appears to provide the best overall survival and progression-free survival especially in patients with high Kadesh grade. On the other hand, surgery alone or biopsy followed with radiation therapy provided the lower progression-free survival and overall survival from time of diagnosis. The role of chemotherapy, however, requires further investigation to assess its potentially harmful effects. The use of surgery as a stand-alone modality of treatment should be cautiously and rarely used in patients with lower staging scores and multiple negative resection margins.

2 September 2020 in Case Reports in Surgery
Verified
Journal Article
Open access
PDF file
MAModhi Alhussinan
Modhi Alhussinan
TETurki Elarjani
Turki Elarjani
MJMohammed Jawhari
Mohammed Jawhari
MAMohammed Albrahim
Mohammed Albrahim
Faisal FarrashFaisal Farrash
Faisal Farrash
Background. Idiopathic intracranial hypertension (IIH) and normal pressure hydrocephalus (NPH) are disorders of the cerebrospinal fluid (CSF) flow dynamics. Pleomorphic xanthoastrocytoma (PXA) is a rare low-grade astrocytoma (World Health Organization grade II) representing <1% of astrocytomas. Combination of IIH and NPH with PXA is unheard of, with few published cases discussing the association of CNS tumors with either IIH or NPH, but never combined. We present a case of a 51-year-old woman with such a rare combination.Case Presentation. A fifty-one-year-old obese female presented with a progressive visual loss, abducens nerve palsy, and headache for three months. Further investigations revealed a right frontal tumor and ventriculomegaly on magnetic resonance imaging. Her symptoms improved remarkably after total surgical excision of the tumor with a ventriculoperitoneal (VP) shunt.Conclusion. The pathophysiology behind NPH and IIH is still not fully understood, yet their management is mostly dependent on CSF diversion. The concomitant development of two different CSF dynamic diseases with a PXA has not been reported in the literature. We hypothesize that PXA may have sparked an abnormal CSF circulation pattern and ventriculomegaly.

14 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
IAItika Arora
Itika Arora
SSShamsa Hilal Saleh
Shamsa Hilal Saleh
AAArshiya Akbar
Arshiya Akbar
FAFareeha Arshad
Fareeha Arshad
VMVolodymyr Mavrych
Volodymyr Mavrych
AYAhmed Yaqinuddin
Ahmed Yaqinuddin
Background/Objectives: Glioblastoma (GBM) is the most lethal primary brain malignancy in adults, with a median overall survival of approximately 15 months. Temozolomide (TMZ) resistance develops in virtually all patients, and no second-line regimen has improved outcomes over the past two decades. The DNA methyltransferase inhibitor decitabine (DAC) has attracted interest as a chemosensitizer, but whether it directly reverses the TMZ-resistance transcriptome or operates through distinct, complementary mechanisms has not been tested at multi-omics resolution. Methods: We performed an integrative six-layer multi-omics analysis across five public GEO datasets (bulk RNA-seq, EPIC 850K methylation, and 21,676 single cells) re-purposed from studies conducted for unrelated aims, formally tested DAC-mediated reversal of the TMZ-resistance transcriptome across 11,707 genes, mapped pharmacogenomic targets with DGIdb v5, and built an exploratory, hypothesis-generating 11-gene prognostic model internally validated in TCGA-GBM (n = 166) and externally tested in the independent CPTAC-GBM cohort (n = 96). Results: DAC reprogrammed transcription across 1114–1882 differentially expressed genes per cohort and reactivated 146 direct epigenetic targets, identifying INPP5D/SHIP1 as the top-ranked direct epigenetic-reactivation target. Genome-wide reversal analysis across 11,707 co-detected genes showed a negligible effect (Spearman ρ = 0.073), but single-cell analysis revealed significant per-cell attenuation of MES-like and stem-like programs (Δ = −0.071 and −0.135, respectively; both p < 0.001). The 11-gene risk model achieved a Harrell’s C-index of 0.706 (apparent); after correcting for the two-stage gene selection with a full-pipeline bootstrap, the optimism-corrected C-index was 0.63, and external validation in an independent cohort (CPTAC-GBM, n = 96) showed only near-chance discrimination (C-index 0.55), indicating that the signature does not generalize and is exploratory. Pharmacogenomic mapping yielded 734 unique therapeutic agents (230 FDA-approved) across 69 druggable targets after excluding AR. Most of these agents are not GBM-directed, so this catalog-level mapping is hypothesis-generating rather than a set of therapeutic recommendations. Conclusions: DAC does not broadly reverse the TMZ-resistant transcriptome but acts through three complementary mechanisms: epigenetic reactivation of INPP5D/SHIP1, cancer-testis-antigen and type I interferon induction, and per-cell attenuation of mesenchymal–stem-like transcriptional intensity, supporting hypotheses for rationally designed DAC-based combination therapy in TMZ-resistant GBM.

29 December 2025 in World Neurosurgery
Verified
Journal Article
Open access
OKOsama Khojah
Osama Khojah
BABalgees Ajlan
Balgees Ajlan
MHMaher Hassounah
Maher Hassounah
BABadriah Alsabbagh
Badriah Alsabbagh
MBMohammed Babgi
Mohammed Babgi
ALAhmed Lary
Ahmed Lary
To describe the clinical features, management, and long-term outcomes of central neurocytoma (CNC). A retrospective cohort included all histopathologically confirmed CNC cases treated at 11 tertiary centers in Saudi Arabia from 1996 to 2021. Overall survival (OS) and progression-free survival (PFS) were estimated with Kaplan-Meier and compared with the log-rank test. Postoperative radiation was modeled as a time-dependent exposure to address immortal time bias. Functional outcomes were assessed with the modified Rankin Scale. A total of 104 patients were identified (mean age 26.9 years, 51.9% male), corresponding to an annual incidence of 14.4 cases per 100 million persons. Most tumors were intraventricular (92.2%). Gross total resection was achieved in 41.3%, subtotal resection in 55.8%, and biopsy only in 2.9%. Postoperative radiation was performed in 40% of cases, with a median interval of 98 days after surgery. The 5-year and 10-year OS were 91.7% and 88.9%, respectively, and PFS were 80.1% and 69.4%, respectively. Neither extent of resection nor postoperative radiation was significantly associated with OS or PFS. Tumors larger than 36.3 cm3 were associated with poorer OS (P = 0.018) and functional outcomes (P = 0.002). At last follow-up, 81.7% of patients maintained functional independence (modified Rankin Scale ≤ 2). CNC offers favorable long-term survival and functional outcomes. Maximal safe resection remains the mainstay of treatment, while the benefit of postoperative radiation appears limited. Tumor size remains a key determinant of outcome.

Verified
Journal Article
Open access
PDF file
FAFareeha Arshad
Fareeha Arshad
NANouran Abualsaud
Nouran Abualsaud
AAArshiya Akbar
Arshiya Akbar
MKMohammed Imran Khan
Mohammed Imran Khan
BRBushra Rasheed
Bushra Rasheed
AYAhmed Yaqinuddin
Ahmed Yaqinuddin
Neuropeptide Y [NPY; encoded by the NPY gene] is a widely expressed 36-amino-acid neuropeptide that regulates neuronal function, vascular regulation, and immune regulation; its role in glioblastoma [GBM] remains incompletely characterized. We performed an integrative in silico multi-scale transcriptomic analysis combining bulk RNA-sequencing of IDH-wildtype GBM [n = 169] and lower-grade glioma [n = 510] surgical resections from TCGA, normal cortical tissue from GTEx [n = 207], and four independent GEO validation cohorts of surgical GBM and non-tumor brain specimens [GSE4290, GSE50161, GSE131928 scRNA-seq of ~20,426 cells from 28 patients, and GSE194329 10X Visium spatial transcriptomics from five patients], along with survival modeling, pathway enrichment, single-cell RNA sequencing, spatial transcriptomics, and cell–cell communication analysis. NPY and its principal receptor, NPY1R, were significantly downregulated in GBM, while genes associated with hypoxia, angiogenesis, invasion, and immune suppression were upregulated. Single-cell analysis showed that NPY-axis transcript expression was elevated in neural progenitor-like populations. In contrast, hypoxia and metabolic programs were concentrated in mesenchymal tumors and stromal compartments, indicating distinct cellular contexts. Spatial analysis revealed a weak and heterogeneous relationship between NPY and hypoxia signatures, with substantial inter-patient variability and no significant global spatial cross-correlation. These findings indicate that loss of NPY signaling is a consistent feature of GBM and is associated with hypoxia-driven tumor states, while the spatial relationship between NPY and hypoxia appears weak, heterogeneous, and patient-specific.